维格列汀对西式饮食小鼠肠道菌群及肠道稳态的影响
维格列汀显著降低盲肠内容物和粪便的DPP-4活性,改变肠道菌群组成与代谢活性,并防止WD诱导的隐窝深度和回肠抗菌肽表达下降,同时降低肝脏免疫细胞群和细胞因子表达。
要点
- 维格列汀显著降低盲肠内容物和粪便的DPP-4活性。
- 维格列汀减少Oscillibacter spp.、增加Lactobacillus spp.和丙酸盐,并减少TLR2/4配体。
- 维格列汀防止WD诱导的隐窝深度和回肠抗菌肽表达下降,并降低肝脏免疫细胞群和细胞因子表达。
核心结论
- 维格列汀对肠道有益效应与调节肠道菌群相关,并对肝脏免疫产生影响。
- 若在人类中相关,可能为DPP-4抑制开拓治疗肠道功能障碍的新用途。
主要发现
- 维格列汀显著降低盲肠内容物和粪便的DPP-4活性。
- 维格列汀主要减少Oscillibacter spp.(对培养的O. valericigenes显示不依赖DPP-4活性的直接效应),增加Lactobacillus spp.和丙酸盐,减少Toll样受体2和4的配体。
- 维格列汀防止WD诱导的隐窝深度和回肠抗菌肽表达下降。
- WD+维格列汀组小鼠肝脏免疫细胞群(Cd3g和Cd11c[亦称Itgax])和细胞因子表达较WD组降低。
- 离体精密肝切片暴露于维格列汀显示该反应与药物对肝组织的直接效应无关。
临床怎么用
- 原文提出维格列汀在肠道水平的有益效应与肠道菌群调节相关,并对肝脏免疫产生影响;若在人类中相关,可能为DPP-4抑制开拓治疗不同病理生理背景下肠道功能障碍的新用途。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Dipeptidyl peptidase 4 (DPP-4) inhibitors are agents designed to increase the half-life of incretins. Although they are administered orally, little is known about their effects on the gut microbiota and functions, despite the fact that some bacteria present in the gut microbiota exhibit DPP-4-like activity. Our objective was to study the impact of the DPP-4 inhibitor vildagliptin on gut functions and the intestinal ecosystem in a murine model of obesity induced by a Western diet (WD). METHODS: Twenty seven male C57BL/6J mice were randomised to receive a control diet, a WD (45% kJ from fat and 17% kJ from sucrose) or a WD + vildagliptin (0.6 mg/ml in drinking water) for 8 weeks. RESULTS: Vildagliptin significantly reduced DPP-4 activity in the caecal content and faeces. Vildagliptin impacted on the composition of the gut microbiota and its metabolic activity. It mainly decreased Oscillibacter spp. (a direct effect independent of DPP-4 activity was shown on cultured O. valericigenes), increased Lactobacillus spp. and propionate, and reduced the ligands of Toll-like receptors 2 and 4. Vildagliptin protected against the reductions in crypt depth and ileal expression of antimicrobial peptides induced by the WD. In the liver, the expression of immune cell populations (Cd3g and Cd11c [also known as Itgax]) and cytokines was decreased in the WD + vildagliptin-fed mice compared with the WD-fed group. Ex vivo exposure of precision-cut liver slices to vildagliptin showed that this response was not related to a direct effect of the drug on the liver tissue. CONCLUSIONS/INTERPRETATION: Our study is the first to consider the DPP-4-like activity of the gut microbiota as a target of DPP-4 inhibition. We propose that vildagliptin exerts beneficial effects at the intestinal level in association with modulation of gut microbiota, with consequences for hepatic immunity. If relevant in humans, this could open new therapeutic uses of DPP-4 inhibition to tackle gut dysfunctions in different pathophysiological contexts. DATA AVAILABILITY: The sequences used for analysis can be found in the MG-RAST database under the project name MYNEWGUT3.
引用
- Olivares M, Neyrinck AM, Pötgens SA, et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia. 2018. PMID: 29797022. doi:10.1007/s00125-018-4647-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。